Exactly!. Yes, at first it will be an added bio expense, but one that could save bigPharma billions on research, and also allow them to focus thier time on other more promising ventures. Spending can be seen as an opportunity cost, and it will be another big driver of why bigPharma will spend upfront. In the biotech world, saving time & money focusing on the wrong thing to instead focus on the right thing it's key. New highs next year, IMHO.
Market Data 
Markets 
AI
